Exercise Capacity in Congenital Heart Disease: The Role of Muscle Metabolism

Exercise Capacity in Congenital Heart Disease: The Role of Muscle Metabolism - Exercise Capacity in Congenital Heart Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45601

Enrollment

Registered

2017-06-08

Start date

2017-09-18

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease decreased exercise tolerance

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Patients with pulmonary arterial hypertension: - Between 8 and 18 years of age - Diagnosis confirmed at the UMC Groningen Patients with a Fontan circulation: - Between 8 and 18 years of age - Diagnosis confirmed by the UMC Groningen - Successfully undergone a Fontan procedure - Stable haemodynamic condition Patients with tetralogy of Fallot: - Between 8 and 18 years of age - Diagnosis confirmed by the UMC Groningen - Successfully undergone procedure to repair the abnormalities;Healthy subjects between 8 and 18 years of age, without significant cardiac defect or known comorbidity affecting exercise tolerance.;All parents and subjects from 12 y.a.o.: Written informed consent

Exclusion criteria

Exclusion criteria: Patients and controls: - age 18 - not familiar with the Dutch language - ineligible to perform an exercise test - with contra-indications for 31P/1H MRS examination - (suspected) pregnancy - mental retardation - with comorbidity affecting exercise tolerance (Anaemia, musculoskeletal injury) - being under examination for non-diagnosed disease at the time of investigation Patients: - with severe complications due to cardiomyopathy/arrhythmia - with exacerbation of disease at time of investigation - with a pacemaker implanted - with severe complications due to epilepsy - with musculoskeletal disease (i.e. muscular dystrophy)

Design outcomes

Primary

Measure	Time frame
o Quadriceps phosphocreatine concentration (PCr) at rest and during progressive exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Quadriceps inorganic phosphorus concentration (Pi) at rest and during exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Quadriceps pH at rest and during exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Post-exercise recovery rate of quadriceps PCr concentration o Post-exercise recovery rate of quadriceps Pi concentration o Post-exercise recovery rate of quadriceps pH	—

Measure

Time frame

o Quadriceps phosphocreatine concentration (PCr) at rest and during progressive exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Quadriceps inorganic phosphorus concentration (Pi) at rest and during exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Quadriceps pH at rest and during exercise (exercise intensities 0-100% of workload corresponding to VO2max) o Post-exercise recovery rate of quadriceps PCr concentration o Post-exercise recovery rate of quadriceps Pi concentration o Post-exercise recovery rate of quadriceps pH

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results